scholarly journals The Ambivalent Function of YAP in Apoptosis and Cancer

2018 ◽  
Vol 19 (12) ◽  
pp. 3770 ◽  
Author(s):  
Xianbin Zhang ◽  
Ahmed Abdelrahman ◽  
Brigitte Vollmar ◽  
Dietmar Zechner
Keyword(s):  
Clinical Trials ◽  
Signaling Pathway ◽  
Clinical Relevance ◽  
Protein A ◽  
Vital Role ◽  
Cancer Drugs ◽  
Good Target ◽  
Anti Cancer ◽  
The Future

Yes-associated protein, a core regulator of the Hippo-YAP signaling pathway, plays a vital role in inhibiting apoptosis. Thus, several studies and reviews suggest that yes-associated protein is a good target for treating cancer. Unfortunately, more and more evidence demonstrates that this protein is also an essential contributor of p73-mediated apoptosis. This questions the concept that yes-associated protein is always a good target for developing novel anti-cancer drugs. Thus, the aim of this review was to evaluate the clinical relevance of yes-associated protein for cancer pathophysiology. This review also summarized the molecules, processes and drugs, which regulate Hippo-YAP signaling and discusses their effect on apoptosis. In addition, issues are defined, which should be addressed in the future in order to provide a solid basis for targeting the Hippo-YAP signaling pathway in clinical trials.

Biological role of AKT, and regulation of AKT signaling pathway by thymoquinone: perspectives in cancer therapeutics

2020 ◽  
Vol 20 ◽  
Author(s):  
Md. Junaid ◽  
Yeasmin Akter ◽  
Syeda Samira Afrose ◽  
Mousumi Tania ◽  
Md. Asaduzzaman Khan
Keyword(s):  
Clinical Trials ◽  
Signaling Pathways ◽  
Signaling Pathway ◽  
Inhibitory Effect ◽  
Akt Signaling ◽  
Review Article ◽  
Therapeutic Drug ◽  
Akt Signaling Pathway ◽  
Anti Cancer

Background: AKT/PKB is an important enzyme with numerous biological functions, and its overexpression is related to the carcinogenesis. AKT stimulates different signaling pathways that are downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase, hence functions as an important target for anti-cancer drugs. Objective: In this review article, we have interpreted the role of AKT signaling pathways in cancer and natural inhibitory effect of Thymoquinone (TQ) in AKT and its possible mechanism. Method: We have collected the updated information and data on AKT, their role in cancer and inhibitory effect of TQ in AKT signaling pathway from google scholar, PubMed, Web of Science, Elsevier, Scopus and many more. Results: There are many drugs already developed, which can target AKT, but very few among them have passed clinical trials. TQ is a natural compound, mainly found in black cumin, which has been found to have potential anti-cancer activities. TQ targets numerous signaling pathways, including AKT, in different cancers. In fact, many studies revealed that AKT is one of the major targets of TQ. The preclinical success of TQ suggests its clinical studies on cancer. Conclusion: This review article summarizes the role of AKT in carcinogenesis, its potent inhibitors in clinical trials, and how TQ acts as an inhibitor of AKT and TQ’s future as a cancer therapeutic drug.

scholarly journals Anticancer Agents from Diverse Natural Sources

2014 ◽  
Vol 9 (11) ◽  
pp. 1934578X1400901 ◽  
Author(s):  
Jabeena Khazir ◽  
Darren L. Riley ◽  
Lynne A. Pilcher ◽  
Pieter De-Maayer ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Anticancer Agents ◽  
Marine Organisms ◽  
New Drugs ◽  
Human Diseases ◽  
Cancer Drugs ◽  
Natural Sources ◽  
Anti Cancer ◽  
Ancient Times

This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.

scholarly journals Repurposed anti-cancer drugs: the future for anti-infective therapy?

2020 ◽  
Vol 18 (7) ◽  
pp. 609-612 ◽  
Author(s):  
Héctor Quezada ◽  
Mariano Martínez-Vázquez ◽  
Esaú López-Jácome ◽  
Bertha González-Pedrajo ◽  
Ángel Andrade ◽  
...  
Keyword(s):  
Cancer Drugs ◽  
Anti Cancer ◽  
The Future

scholarly journals Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions

2021 ◽  
Vol 17 (5) ◽  
pp. 265-271 ◽  
Author(s):  
Muhammad Awidi ◽  
Samer Al Hadidi
Keyword(s):  
Clinical Trials ◽  
Black Americans ◽  
Cancer Therapeutics ◽  
Fundamental Unit ◽  
Cancer Clinical Trials ◽  
Cancer Drugs ◽  
The Future

Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that a prompt improvement of Black Americans participation is warranted.

scholarly journals Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 418 ◽  
Author(s):  
Yoshikatsu Koga ◽  
Atsushi Ochiai
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Solid Tumors ◽  
Cancer Biology ◽  
Drug Efficacy ◽  
Cancer Drugs ◽  
Personalized Care ◽  
Patient Derived Xenograft ◽  
Anti Cancer ◽  
Pdx Models

Patient-derived xenograft (PDX) models are used as powerful tools for understanding cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus on PDX clinical trials or co-clinical trials for drug development in solid tumors and summarize the utility of PDX models in the development of anti-cancer drugs, as well as the challenges involved in this approach, following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Recently, the assessment of drug efficacy by PDX clinical and co-clinical trials has become an important method. PDX clinical trials can be used for the development of anti-cancer drugs before clinical trials, with their efficacy assessed by the modified response evaluation criteria in solid tumors (mRECIST). A few dozen cases of PDX models have completed enrollment, and the efficacy of the drugs is assessed by 1 × 1 × 1 or 3 × 1 × 1 approaches in the PDX clinical trials. Furthermore, co-clinical trials can be used for personalized care or precision medicine with the evaluation of a new drug or a novel combination. Several PDX models from patients in clinical trials have been used to assess the efficacy of individual drugs or drug combinations in co-clinical trials.

scholarly journals Anti-Cancer Activity of Derivatives of 1,3,4-Oxadiazole

Molecules ◽  
2018 ◽  
Vol 23 (12) ◽  
pp. 3361 ◽  
Author(s):  
Teresa Glomb ◽  
Karolina Szymankiewicz ◽  
Piotr Świątek
Keyword(s):  
Biological Activity ◽  
Growth Factors ◽  
Cell Lines ◽  
Cancer Drugs ◽  
Inhibition Of Growth ◽  
Anti Cancer ◽  
The Future ◽  
Derivatives Of ◽  
Cancer Activity

Compounds containing 1,3,4-oxadiazole ring in their structure are characterised by multidirectional biological activity. Their anti-proliferative effects associated with various mechanisms, such as inhibition of growth factors, enzymes, kinases and others, deserve attention. The activity of these compounds was tested on cell lines of various cancers. In most publications, the most active derivatives of 1,3,4-oxadiazole exceeded the effect of reference drugs, so they may become the main new anti-cancer drugs in the future.

Research Nurses for Clinical Trials of Anti-Cancer Drugs: Developing a New Subspecialty in Taiwan

1998 ◽  
Vol 32 (1_suppl) ◽  
pp. 1279S-1281S
Author(s):  
Ann-Lii Cheng ◽  
Yuer-Hur Lai ◽  
Yu-Chieh Yu
Keyword(s):  
Clinical Trials ◽  
Cancer Drugs ◽  
Anti Cancer ◽  
Research Nurses

Orthodontic Bonded Retainers: a Narrative Review

Dental Update ◽  
2020 ◽  
Vol 47 (5) ◽  
pp. 421-432 ◽  
Author(s):  
Maurice J Meade ◽  
Declan T Millett
Keyword(s):  
Clinical Trials ◽  
Clinical Relevance ◽  
Orthodontic Treatment ◽  
Randomized Clinical Trials ◽  
Treatment Compliance ◽  
Post Treatment ◽  
Narrative Review ◽  
Dental Practitioners ◽  
The Future ◽  
Bonded Retainers

Indefinite retention is now considered essential to prevent relapse after orthodontic treatment. Compliance with removable retainer wear is suboptimal and appears to decline with time post-treatment. As a result, use of bonded retainers may become more commonplace in the future. In this narrative review, the characteristics of bonded retainers are outlined and a summary of the evidence from randomized clinical trials regarding their effectiveness is provided. Guidance is also offered regarding care and maintenance. CPD/Clinical Relevance: All general dental practitioners (GDPs) should be familiar with types of bonded retainers, evidence relating to their effectiveness and the GDP's role regarding their care and maintenance.

Sign in / Sign up

Export Citation Format

Share Document